Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1057Stomach Neoplasms 802Carcinoma, Hepatocellular 785Pancreatic Neoplasms 577Rectal Neoplasms 449Colonic Neoplasms 405Esophageal Neoplasms 363Liver Neoplasms 225Esophageal Squamous Cell Carcinoma 144Neoplasms 134Cholangiocarcinoma 129Neoplasm Metastasis 117Breast Neoplasms 117Gastrointestinal Neoplasms 105Lung Neoplasms 76Biliary Tract Neoplasms 73Recurrence 61Prostatic Neoplasms 52Ovarian Neoplasms 49Barrett Esophagus 47Carcinoma, Non-Small-Cell Lung 44Anastomotic Leak 43Bile Duct Neoplasms 42Gastrointestinal Stromal Tumors 40Gallbladder Neoplasms 40Head and Neck Neoplasms 38Digestive System Neoplasms 35Anus Neoplasms 34Colonic Polyps 33Adenocarcinoma Of Esophagus 32

Interventions

tislelizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Potentially Resectable Locally Advanced Malignant Tumors of Biliary System × Gastrointestinal × Clear all
NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡